Trial Profile
Long-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Degenerative myopia
- Focus Therapeutic Use
- 15 Dec 2015 New trial record